Raclopride

N/A

Report date: 2024/01/02 20:03:52
NME

Base Information

Drug NameRaclopride
Drug Alias Nameraclopride雷氯必利raclopridumraclopridaFLA-870 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D2 receptor antagonists
TargetsDopamine D2 receptor
Therapy Area/IndicationsAttention Deficit Disorder with HyperactivityDepressionCocaine-Related Disorders +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSweden
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesYale University
Inactive CompaniesNational Institute On Alcohol Abuse And AlcoholismUniformed Services University Of The Health SciencesAstrazeneca Plc
Active IndicationsAttention Deficit Disorder with Hyperactivity
Inactive IndicationsDepressionCocaine-Related DisordersBrain Injuries, Traumatic

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG